peripheral neuropathic pain pipeline insight

DelveInsight’s, “Peripheral Neuropathic Pain - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Peripheral Neuropathic Pain  pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.  

Geography Covered

• Global coverage

Peripheral Neuropathic Pain: Understanding

Peripheral Neuropathic Pain: Overview

Neuropathic pain is a particularly distressing chronic pain syndrome, affecting between 2% and 8% of people with a major impact on quality of life. Peripheral neuropathic pain, defined as ‘Pain caused by a lesion or disease of the peripheral somatosensory nervous system’ , is a common and challenging chronic pain syndrome, with a range of diverse aetiologies. Broadly speaking, these can be divided into neural damage as a result of systemic processes such as disease, toxins, or drugs, often with a classical ‘glove and stocking’ distribution; or secondary to local damage such as trauma, surgery, or locally invasive malignancy.

Neuropathic pain is a particularly distressing chronic pain syndrome, affecting between 2% and 8% of people with a major impact on quality of life. Peripheral neuropathic pain, defined as ‘Pain caused by a lesion or disease of the peripheral somatosensory nervous system’ , is a common and challenging chronic pain syndrome, with a range of diverse aetiologies. Broadly speaking, these can be divided into neural damage as a result of systemic processes such as disease, toxins, or drugs, often with a classical ‘glove and stocking’ distribution; or secondary to local damage such as trauma, surgery, or locally invasive malignancy.

Neuropathic pain syndromes typically have both negative and positive sensory symptoms and signs. Nonsensory neurological symptoms and signs depend on the underlying cause and may independently contribute to pain and disability. Although neuropathic pain has been defined by the International Association for the Study of Pain as pain "initiated or caused by a primary lesion or dysfunction in the nervous system,"4(p212) several investigators have recently argued that the inclusion of the term dysfunction makes this definition vague and unacceptably broad. A proposed solution is to define neuropathic pain as pain caused by a lesion of the peripheral or central nervous system (or both) manifesting with sensory symptoms and signs. The diagnosis of neuropathic pain is based on a medical history, review of systems, physical and neurological examination, and appropriate laboratory studies including blood and serologic tests, magnetic resonance imaging, and electrophysiologic studies. In some instances, nerve or skin biopsy is necessary to directly visualize nerve fibers.

Treatment for peripheral neuropathic pain includes medications like anti-seizure drugs (gabapentin, pregabalin), antidepressants (amitriptyline, duloxetine), and topical agents (lidocaine, capsaicin). Non-drug therapies such as physical therapy, acupuncture, and TENS can help, along with lifestyle changes like healthy eating, exercise, and avoiding alcohol or smoking. Severe cases may require advanced interventions like spinal cord stimulation or plasma exchange.

“Peripheral Neuropathic Pain - Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Peripheral Neuropathic Pain pipeline landscape is provided which includes the disease overview and Peripheral Neuropathic Pain treatment guidelines. The assessment part of the report embraces, in depth Peripheral Neuropathic Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peripheral Neuropathic Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Peripheral Neuropathic Pain R&D. The therapies under development are focused on novel approaches to treat/improve Peripheral Neuropathic Pain. 

Peripheral Neuropathic Pain Emerging Drugs Chapters

This segment of the Peripheral Neuropathic Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peripheral Neuropathic Pain Emerging Drugs

• Suzetrigine: Vertex Pharmaceuticals

Suzetrigine (formerly VX-548) is an investigational oral, selective NaV1.8 pain signal inhibitor that is highly selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that plays a critical role in pain signaling in the peripheral nervous system. NaV1.8 is a genetically validated target for the treatment of pain, and suzetrigine has demonstrated a favorable benefit/risk profile in three Phase III studies and two Phase II studies in moderate-to-severe acute pain. Suzetrigine also demonstrated positive results and a well-tolerated profile in a Phase II study in patients with pain associated with diabetic peripheral neuropathy, a type of peripheral neuropathic pain. Vertex’s approach is to selectively inhibit NaV1.8 using small molecules with the objective of creating a new class of pain signal inhibitors that have the potential to provide effective relief of pain without the limitations of currently available therapies, including the addictive potential of opioids.

• LX9211: Lexicon Pharmaceuticals

Lexicon’s unique approach to gene science, pilavapadin (LX9211) is a potent, once-daily, orally delivered, selective, investigational small molecule inhibitor of AAK1, a novel target for neuropathic pain which inhibits reuptake and recycling of neurotransmitters involved in pain signaling without affecting opiate pathways. Lexicon identified AAK1 in its target discovery efforts as a promising approach for the treatment of neuropathic pain. Preclinical studies of pilavapadin demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways. Currently the drug is in Phase II stage of its clinical trial for the treatment of Peripheral Neuropathic Pain.

• AFA-281: Afasci

AFA-281 is a novel, orally administered small molecule developed by AfaSci that acts as a dual inhibitor of T-type calcium channels (specifically Cav3 subtypes) and soluble epoxide hydrolase (sEH). Its mechanism of action (MOA) involves blocking Cav3 channels, which are upregulated in conditions like neuropathic and inflammatory pain, thereby reducing neuronal hyperexcitability and pain signaling. Simultaneously, AFA-281 inhibits sEH, an enzyme that degrades anti-inflammatory epoxy-fatty acids (EpFAs) into pro-inflammatory diols, thus helping to maintain anti-inflammatory signaling and further alleviating pain and neuroinflammation. This dual action provides both analgesic and anti-inflammatory effects, making AFA-281 a promising non-opioid candidate for treating neuropathic pain, inflammatory pain, and substance use disorders, with demonstrated efficacy in preclinical models and a favorable safety profile in early clinical studies.

Further product details are provided in the report…….

Peripheral Neuropathic Pain: Therapeutic Assessment

This segment of the report provides insights about the different Peripheral Neuropathic Pain drugs segregated based on following parameters that define the scope of the report, such as:

Major  Players in Peripheral Neuropathic Pain 

There are approx. 10+ key companies which are developing the therapies for Peripheral Neuropathic Pain. The companies which have their Peripheral Neuropathic Pain drug candidates in the most advanced stage, i.e. Phase III include Vertex Pharmaceuticals.

Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Peripheral Neuropathic Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Intra-articular
• Intraocular
• Intrathecal 
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peripheral Neuropathic Pain: Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Peripheral Neuropathic Pain therapeutic drugs key players involved in developing key drugs. 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peripheral Neuropathic Pain drugs.

Peripheral Neuropathic Pain Report Insights

• Peripheral Neuropathic Pain  Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Peripheral Neuropathic Pain Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Peripheral Neuropathic Pain drugs?
• How many Peripheral Neuropathic Pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peripheral Neuropathic Pain?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Peripheral Neuropathic Pain therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Peripheral Neuropathic Pain and their status?
• What are the key designations that have been granted to the emerging drugs?